Skip to main content
. 2021 Oct 19;28(5):4234–4246. doi: 10.3390/curroncol28050359

Figure 3.

Figure 3

Patients with advanced-stage HGSOC with a low density of omental CD68+ or CD163+ om-TAMs had a poor prognosis in terms of OS. (A,B) Patients with a low density of omental CD68+ or CD163+ om-TAMs had poor OS (median survival: 27 vs. 47 months; 26 vs. 46 months, p = 0.023; p = 0.098). (C,D) The density of omental CD68+ or CD163+ om-TAMs was not associated with PFS (median survival: 13 vs. 20 months; 13 vs. 18 months, p = 0.225, p = 0.547). (E,F) The ratio of omental CD68+/ CD163+ om-TAM was not associated with OS or PFS (p = 0.50; p = 0.299).